JAZZJazz Pharmaceuticals plc
Compact View
Earnings Recap
• Reported GAAP EPS of $4.73 up 411.18% YoY • Reported revenue of $1.07B up 19.05% YoY • Jazz Pharmaceuticals expects total revenues in 2026 to increase, driven by oncology and epilepsy products, offset by reduced oxybate revenues. The company anticipates SG&A expenses to decrease and R&D expenses to increase in 2026.
Bullish
Jazz Pharmaceuticals achieved strong product sales growth for Xywav, Epidiolex/Epidyolex, and Zepzelca, alongside successful launches of Modeyso and Ziihera. Positive Phase 3 trial results also support strategic pipeline advancements.
Bearish
Jazz Pharmaceuticals faces challenges from increased generic competition impacting Xyrem sales, ongoing patent litigation across key products, and negative foreign currency translation adjustments affecting intangible assets.